Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFAMOSI: Afatinib followed by Osimertinib vs Osimertinib in EGFR+ NSCLC
NCT04413201Phase 4Active, not recruiting
- Start
- Sep 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of afatinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC). Started Sep 2020; status: active, not recruiting.
02
Drugs
afatinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04413201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04413201.